Home > Boards > US OTC > Biotechs >

Rezolute Inc. (RZLT)

RZLT RSS Feed
Add RZLT Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 9/22/2020 2:16:10 PM - Followers: 11 - Board type: Free - Posts Today: 0

AntriaBioAntriaBio, Inc.
890 Santa Cruz Avenue
Menlo Park, CA 94025
P: (650) 223-5441
info@antriabio.com

Reverse Merger 


Jan 7, 2013 - AntriaBio, Inc., a biopharmaceutical company developing novel therapeutics for the diabetes market, is pleased to announce the acquisition of the significant assets of PR Pharmaceuticals, Inc. and its intention to become a publicly traded company through a merger.

"AB101 has the potential to be a clearly differentiated product that represents a significant advance in basal insulin delivery," said Nevan Elam, AntriaBio's President and CEO. "AB101 may offer significant advantages over basal insulin products sold by Sanofi-Aventis and Novo Nordisk, which together sell more than $7B annually."



AntriaBio's lead diabetes product candidate, AB101, is a once-a-week injectable basal insulin that is currently in preclinical development. AB101 is administered by subcutaneous injection and targets patients with type 1 and type 2 diabetes who require basal insulin for the control of hyperglycemia.

The formulation has been designed to release insulin slowly and uniformly over a period of approximately one week without an adverse initial burst of insulin. The release profile results in a low and sustained insulin level which supplements the effects of endogenous and exogenous insulin and complements the effects of orally administered hypoglycemic agents. AB101 has the potential to be a clearly differentiated product that represents a significant advance in basal insulin delivery.

AB101's long duration of action is the result of our ability to PEGylate insulin and then encapsulate it into poly-lactic, poly-glycolic (PLGA) microspheres. Currently available PEGylated biomolecules typically use large molecular weight PEG chains to decrease clearance and therefore reduce injection frequency. However, we use a very small molecular weight PEG for AB101 to modify the solubility of insulin and permit encapsulation of the drug into a biodegradable polymer.

After injection, the PEGylated insulin is slowly released at the injection site as the polymer microspheres are broken down by simple hydrolysis. Not only is our technology is unique, but also AB101 does not contain any new excipients and regulatory authorities have already approved numerous products using PEG or biodegradable polymers.

In addition to the proprietary technology for PEGylation of insulin and incorporation of the PEGylated insulin into biodegradable polymers, we have licensed proprietary microparticle manufacturing technology. The microsphere manufacturing process ensures production of a very tight particle size distribution with uniformly small microparticles. This is important to improve manufacturing efficiency and yields as well as to facilitate patient comfort by producing microspheres that can be injected through 25 gauge or smaller needles.



 

AntriaBio Appoints Two Industry Leaders to its Management Team
 
Menlo Park, CA - February 19th, 2013 - AntriaBio, Inc. is pleased to announce the appointment, on January 31, 2013, of two new members to its management team: Nevan Elam, AntriaBio's President and Chief Executive Officer and Sankaram Mantripragada, Ph.D, as AntriaBio's Chief Scientific Officer.
 
Nevan Elam has spent his entire career starting, managing and advising emerging growth companies in key areas of business including finance, marketing and clinical development. Prior to joining AntriaBio, Mr. Elam served as Chief Executive Officer of AeroSurgical Limited, a medical device company based in Europe. Prior to that, he directed the Pulmonary Business Unit of Nektar Therapeutics, which was sold to Novartis in 2008.
 
Mr. Elam also serves as a managing director of Konus Advisory Group, Inc. ("Konus"), a boutique healthcare consulting and investment firm that specializes in working with U.S. and European healthcare organizations on business opportunities in Asia, Latin America and the Middle East. Mr. Elam holds a J.D. from Harvard University and Bachelor's degree from Howard University.
 
Sankaram Mantripragada, Ph.D. brings to AntriaBio his strong understanding of the diabetes market and AntriaBio's unique platform technology. From June 2005 until October 2009, Dr. Mantripragada served as Vice President of R&D at PR Pharmaceuticals, Inc. ("PRP"). In January 2013, AntriaBio purchased substantially all of the PRP assets including significant technology, formulation, manufacturing, and intellectual property assets, which together form the basis of AntriaBio's drug development portfolio.
 
"Dr. Mantripragada's history with PRP's technology and formulation assets and his deep experience in diabetes products and markets make him a clear choice to lead our product development efforts," said Steve Howe, Chairman of AntriaBio. Mr. Howe served as Chairman and Chief Executive Officer of PRP from its formation in 1998 to 2010.
 
Dr. Mantripragada has been an advisor to companies specializing in diabetes, cell based therapies and cardiovascular diseases. He is listed as an inventor on more than 8 patents.
 
Prior to joining PRP, Dr. Mantripragada served as Director of R&D at Guidant Corporation, now part of Abbott Vascular. Prior to that, he served as Director of R&D and VP of Scientific Development at SkyePharma. Prior to that, he was an Assistant Professor of Biochemistry at the University of Virginia School of Medicine. Dr. Mantripragada obtained his Ph.D. in Molecular Biophysics from the Indian Institute of Science and completed a postdoctoral research program at the Max Planck Institute for Biophysical Chemistry in Germany.
 

 


chart
 
RZLT
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
RZLT News: Statement of Changes in Beneficial Ownership (4) 09/25/2020 11:14:47 AM
RZLT News: Statement of Changes in Beneficial Ownership (4) 09/23/2020 11:13:01 AM
RZLT News: Statement of Changes in Beneficial Ownership (4) 09/21/2020 10:31:37 AM
RZLT News: Statement of Changes in Beneficial Ownership (4) 09/18/2020 11:26:17 AM
RZLT News: Statement of Changes in Beneficial Ownership (4) 09/15/2020 11:36:28 AM
PostSubject
#159   www.stockscores.com/chart.asp?TickerSymbol=RZLT&TimeRange=1825&Interval=w mick 09/22/20 02:16:10 PM
#158   It looks like insider Handok is buying 125,000 daleb2130 09/21/20 12:02:42 PM
#157   THANK YOU Rezolute Inc (QB) (RZLT) mick 09/15/20 08:16:24 PM
#156   RZLT And another 125,000 buy by Handok @.4908 daleb2130 09/15/20 08:12:50 PM
#155   #2 Rezolute Inc (QB) (RZLT) mick 09/14/20 02:15:47 PM
#154   Rezolute Inc (QB) (RZLT) mick 09/14/20 02:15:21 PM
#153   Rezolute Inc (QB) (RZLT) mick 09/14/20 02:15:21 PM
#152   dont get shook, its all games....onward and upward TrendTrade2016 09/08/20 05:30:44 PM
#151   Yup. Thanks for those .41's whoever panicked. Large daleb2130 09/08/20 04:05:44 PM
#150   BOOM!!! back above.50 kanonman 09/08/20 03:58:34 PM
#149   I just bought more myself. Im going to daleb2130 09/08/20 01:07:05 PM
#148   another block of 125000 bought by insiders today. kanonman 09/08/20 11:14:07 AM
#147   precision trading...called every move to perfection to .65c...its TrendTrade2016 09/05/20 06:42:09 AM
#146   2 more Hadcock buys for 125,000 shares each. daleb2130 09/04/20 07:39:09 PM
#145   more churn today... kanonman 09/03/20 02:25:15 PM
#144   100% BUY kanonman 09/03/20 01:46:14 AM
#143   WTF you talking about. 3 month chart ...... daleb2130 09/02/20 09:56:37 PM
#142   Legendary beebread 09/02/20 07:01:04 PM
#141   With insider buying good sized quantities you would brianslate 09/02/20 01:53:36 PM
#140   yup kanonman 09/02/20 09:48:27 AM
#139   Another 125,000 insider buy daleb2130 09/02/20 08:38:30 AM
#138   The monster has been released, it is now TrendTrade2016 09/01/20 12:45:27 PM
#137   It will sooner or later. daleb2130 09/01/20 12:40:39 PM
#136   needs to stay above .60 though kanonman 09/01/20 12:39:14 PM
#135   A good start today daleb2130 09/01/20 12:38:13 PM
#134   the reason they are buying shares, they are TrendTrade2016 08/29/20 11:03:20 AM
#133   loose...but it needs a week. TrendTrade2016 08/29/20 11:00:34 AM
#132   I would say almost a lock that something daleb2130 08/28/20 10:31:53 PM
#131   and more today.... always a good sign kanonman 08/28/20 09:46:19 PM
#130   let it lose or let it LOOSE? kanonman 08/28/20 09:44:43 PM
#129   http://archive.fast-edgar.com/20200828/AWZKA22CZC2232ZY222O2CZZSJRFZZR8Z222 kanonman 08/28/20 09:42:58 PM
#128   Handok Inc. seems to buy more shares every daleb2130 08/28/20 06:42:41 PM
#127   RZLT enough is enough......time to let this lose!! TrendTrade2016 08/28/20 02:39:16 PM
#126   Insiders keep buying. Always a good thing....... 5 daleb2130 08/25/20 05:01:03 PM
#125   it got close...back below .50 again...really wants to kanonman 08/25/20 02:22:23 PM
#124   Yes they are.... daleb2130 08/25/20 10:12:19 AM
#123   HERE WE GO....60'S COMING IN FAST!!! TrendTrade2016 08/25/20 09:28:34 AM
#122   GAPPA DAPPA DOO!! 53X54!!!ZOOOM!!! TrendTrade2016 08/25/20 09:15:30 AM
#121   Much More daleb2130 08/24/20 08:28:30 PM
#120   more to come!! TrendTrade2016 08/24/20 05:37:20 PM
#119   Nice call on RZLT$. This has been a SILVER HARVEST 08/24/20 05:26:07 PM
#118   RZLT little bit of consolidation up here as TrendTrade2016 08/23/20 07:40:00 AM
#117   RZLT next week we see the 50's come TrendTrade2016 08/22/20 06:51:55 AM
#116   bye buy NITE!!!! TrendTrade2016 08/18/20 10:05:03 AM
#115   HERE WE GO...MONSTA PUSH TO .65C WHOS TrendTrade2016 08/18/20 09:52:19 AM
#114   RZLT heading to .54c then 57c and the TrendTrade2016 08/18/20 06:16:15 AM
#110   next week we see 54c TrendTrade2016 08/14/20 04:19:21 PM
#109   Ready for 50s next week then the fun TrendTrade2016 08/14/20 03:09:36 PM
#108   forming new base...the 30's are the new 20's TrendTrade2016 08/13/20 04:43:00 PM
#107   pit stop The Night Stalker 08/13/20 12:10:13 AM
PostSubject
Consent Preferences